Trial Profile
A Phase I, Single Centre, Open-Label, Non-Randomised Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental (Pentoxifylline) Administered to Healthy Subjects Under Fed Conditions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs PCS 499 (Primary)
- Indications Diabetic nephropathies
- Focus Pharmacokinetics
- Sponsors Processa Pharmaceuticals
- 19 Oct 2011 Results were presented at the American Society of Nephrology's (ASN) Kidney Week 2011, according to a Concert Pharmaceuticals media release.
- 22 Jun 2011 New trial record